pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Tevimbra
drug · antibody
save

Tevimbra

Phase 3updated 3mo ago
by $ONC BeOne Medicines Ltd.🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 1
  • tagApproval48 co-mentions · 12 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 50 investigational indications.

indications

indications
NSCLC

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

News(3)

  • Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
    Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
    biospace · 24d ago
  • Akeso, Summit drug extends survival in closely watched lung cancer trial
    Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.
    biopharma_dive · 2mo ago
  • OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
    Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
    onclive · 3mo ago
brand
Tevimbra
trade names
Tevimbra, Tizveni
generic
tislelizumab-jsgr
MOA
Programmed cell death protein 1 inhibitor
indication
Small-Cell Lung Cancer
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 40m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?